Outpatient Liquid Aspirin (OLA)

Covid19 Clinical Trial

— OLA COVID  

Official title:

Outpatient, Liquid Aspirin to Reduce COVID-19 Hospitalizations

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04937088
• Other study ID #: 1658
• Status: Recruiting
• Phase: Phase 2
• Start date: December 6, 2021
• Est. completion date: December 5, 2022

Study information

• Verified date: December 2021
• Source: Louisiana State University Health Sciences Center in New Orleans
• Contact: Frank Lau, MD
• Phone: 504-412-1240
• Email: flau[@]lsuhsc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to obtain reliable and interpretable data to inform future trials regarding our hypothesis that a novel, liquid aspirin formulation can mitigate COVID -19 associated coagulopathy (CAC) . The potential impact is to reduce COVID-19 related hospitalization within 30 days of diagnosis due to (1) pulmonary events including respiratory failure; (2) cardiac events including myocardial infarction and myocarditis (3) venous or arterial thrombotic events; (4) acute renal insufficiency or failure.

Description:

200 people will take part in this LSUHSC-NO and its affiliates study.

The clinical site will offer study enrollment to newly diagnosed COVID-19 patients at the time of diagnosis. Contact information will be shared with study team in a HIPAA compliant manner on the same day. Within 24 hours, our Study staff will contact patient for recruitment and enrollment. Within 48 hours of enrollment, the patient will come to a study site for randomization to treatment arms, to be provided a no-cost supply of the treatment which they are assigned, and for blood draws that help determine their risk of developing severe COVID disease. Patients will be assigned to either:

Arm 1: Placebo

Or

Arm 2: Treatment with liquid aspirin 150 mg daily. (ASA 150).

Study staff will follow-up every 2 days for a total of 30 days by text/phone/telemedicine to monitor changes in their health status, hospitalization rates, and encourage adherence to the treatment arm. Between days 7 and 10 of the study, patients will undergo repeat blood draws to help ensure their safety with regards to COVID-19. If they become hospitalized due to COVID-19, their participation will extend until they are discharged from the hospital. Medical records will be reviewed to collect data including demographics, medical comorbidities, laboratory data and hospitalization course. After 30 days of treatment, weekly follow up for another 30 days will take place ensure no late, adverse events occurred.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 5, 2022
• Est. primary completion date: December 5, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Patients > 40 years

• Written informed consent

• New (within 24 hours) COVID-19 diagnosis

• Serum 25OHD levels drawn at time of COVID-19 laboratory workup

Exclusion Criteria:

• Asymptomatic patients

• Patients already taking ASA and other anti-coagulant / anti-platelet therapies including but not limited to clopidogrel, heparin, low molecular weight heparin, coumadin, apixaban.

• Pregnant patients or prisoners

• History of GI bleeding or peptic ulcer disease, or spontaneous bleeding from other sites

• Thrombocytopenia (platelets <130,000/uL) at time of COVID diagnosis

• Anemia at time of COVID diagnosis (defined as hemoglobin level <12 g/dl in men or <11 g/dl in women)22

• History of chronic kidney disease

• Concurrent use of nonsteroidal anti-inflammatory drugs, or steroids

• Hypervitaminosis D and associated risk factors: Renal failure, Liver failure, Hyperparathyroidism, Sarcoidosis, Histoplasmosis

• Known allergy to Aspirin

• Inability to tolerate oral medications

• Known history of aspirin-induced asthma

• History of bleeding problems

• Patients who cannot avoid drinking 3 or more alcoholic drinks every day during the 30-day course of ASA treatment

• Patients who cannot stop taking other nonprescription NSAIDs (ibuprofen, naproxen, or others) during the 30-day course of ASA treatment

• Patients requiring hospitalization (for any reason) at time of screening

• Patients taking or who plan to take on an outpatient basis remdisivir, dexamethasone, or other therapies for treatment of COVID

Related Conditions & MeSH terms

• COVID-19
• Covid19

Intervention

Drug:
• ASA
Liquid aspirin formulation

Locations

Country	Name	City	State
United States	Lsuhsc-No	New Orleans	Louisiana

Sponsors (2)

Lead Sponsor	Collaborator
Louisiana State University Health Sciences Center in New Orleans	Innovate Anti-Infectives

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduced COVID-19 related hospitalizations	To obtain reliable and interpretable data to inform future trials regarding our hypothesis that a 30 day treatment course of COVID patients with a novel, liquid aspirin formulation can reduce hospitalizations driven by COVID associate coagulopathy (CAC)	6 months